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PCI and follow up intravascular ultrasound (IVUS, mean 9.9±2.4 months) were
performed in all patients.
Results: The Post-PCI external elastic membrane (EEM) volume (group I vs group II,
417.3±196.5 vs 409.7±180.1 mm3, p=NS), post-PCI lumen volume (228.6±111.0 vs
223.0±89.5 mm3, p=NS), follow up EEM volume (435.1±168.1 vs 414.9±179.4 mm3,
p=NS), and follow up lumen volume (236.6±91.7 vs 222.5±90.1 mm3, p=NS) by IVUS
were not different between the two groups. There were three LISAs [2.5%, group I
(n=2) vs group II (n=1)] and thirty four PISAs [28.1%, group I (n=23) vs group II
(n=11)] that were resolved [14.7%, group I (n=4) vs group II (n=1)]. Post-PCI and
follow up volume of PISA was not significantly different in both group I (5.9±5.6 vs
5.1±4.6 mm3, p=NS) and group II (8.9±4.4 vs 8.5±4.2 mm3, p=NS). There was no
major adverse cardiac event associated with LISA or PISA during 12-month clinical
follow up.
Conclusion: The incidence of LISA was very low in both groups comparing to the
previous generation of drug eluting stent. Both LISA and PISA were not associated
with cardiac events during 12-month follow up. Future long-term follow up study to
clarify the clinical impacts of LISA and PISA would be needed.
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Background: We studied the long term outcome of patients with isolated proximal
LAD disease revascularised with either DES or ‘off-pump’ left internal mammary
artery (LIMA) graft.
Methods: 874 consecutive patients with stable angina undergoing either elective
percutaneous coronary intervention with a DES or ‘off-pump’CABG for significant
isolated proximal LAD disease at a London centre between Oct 2003-December 2010
were studied. The primary end point used was major adverse cardiac events (MACE),
defined as the composite of death, myocardial infarction (MI), stroke and target vessel
revascularization (TVR).
Results: 752 patients underwent PCI with DES and 122 pts underwent ‘off-pump’
CABG. The baseline demographic and angiographic characteristics were similar
between the two groups. The mean duration of hospitalization after CABG was 6.33
± 1.61 days vs. 1.06 ± 0.20 days after PCI (P < 0.001). Kaplan-Meier estimates of
major adverse cardiac events showed no differences between the groups over the
follow-up period (11.8% vs 12.0%, p=0.9 at 4 years) (Figure 1a). On MACE
breakdown there was a trend towards higher mortality in the LIMA cohort (7.8% vs
4.2%, p = 0.12) with a trend towards higher TVR in the DES group (5.8% vs 2.8%,
p=0.19) (Figure 1b). After multivariate adjustment revascularisation technique was not
predicative of major-adverse cardiac events.
Conclusion: The study demonstrated that DES have similar long-term results to LIMA
regarding MACE events in patients with isolated proximal LAD disease.
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Background: The aim of this study was to evaluate the frequency, predictors and the
clinical outcome of stent thrombosis after DES implantation and bare metal stent
(BMS) implantation in Asian races.
Methods: A total of 14,577 consecutive patients who underwent successful DES
implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38%
of the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients)
were included in this study. We evaluate the frequency, predictor of stent thrombosis.
Results: At a mean follow-up of 78.5±29.9 months in DES and 81.8±26.4 months in
BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis
(SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18%
with DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year
with DES and no BMS. Independent predictors of stent thrombosis are bifurcation
lesion (OR=1.90, 95% CI: 1.83 to 24.24, p=0.01) and ejection fraction (OR=0.90, 95%
CI: 0.86 to 0.94, p=0.03). Only 0.2 % of the patients were died because of the
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myocardial infarction after stent thrombosis in both groups.
Conclusion: The incidence of stent thrombosis in Asian races is relatively low (0.5 %
with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent
thrombosis) at mean follow-up to 6 years. Particular attention will need to be directed
to this complication when the patients have bifurcation lesions or low ejection fraction.
TCT-211
The SYNTAX Trial at 3 Years: A Global Risk Approach to Identify Patients
With 3-Vessel &/or Left Main Stem Disease Who Could Safely & Efficaciously
Be Treated With Percutaneous Coronary Intervention Part 2: The All-Comers
SYNTAX Population
Vasim Farooq1, Patrick W Serruys1, David R Holmes2, Arie-Pieter Kappetein3,
Michael Mack4, Ted Feldman5, Marie-Claude Morice6, Elisabeth Ståhle7, Antonio
Colombo8, Peggy Pereda9, Jian Huang9, Marie A Morel10, Gerrit Anne Van Es10,
Keith D D Dawkins9, Friedrich W Mohr11, Ewout W Steyerberg12
1Department of Interventional Cardiology, Erasmus University Medical Centre,
Thoraxcenter, Rotterdam, Netherlands; 2The Mayo Clinic, Rochester, MN;
3Department of Cardiothoracic Surgery, Erasmus University Medical Centre,
Thoraxcenter, Rotterdam, Netherlands; 4Medical City Dallas Hospital, Dallas, TX;
5Evanston Hospital, Evanston, IL; 6Institut Jacques Cartier, Massy, France, Paris,
France; 7University Hospital Uppsala, Uppsala, Sweden; 8San Raffaele Scientific
Institute, Milano, Italy; 9Boston Scientific Corporation, Natick, Boston, MA;
10Cardialysis BV, Rotterdam, Netherlands; 11Herzzentrum, Leipzig, Germany;
12Department of Public Health, Erasmus University Medical Center, Rotterdam,
Netherlands
Background: The Global Risk Categorisation (GRC), a combination of the SYNTAX
score (SXscore) & additive EuroSCORE, is superior to the SXscore alone in predicting
clinical outcomes in patients with 3VD &/or LMS coronary disease undergoing PCI.
The GRC is investigated in the All-Comers “real-world” SYNTAX population.
Methods: The study population (n=3075) consisted of pre-specified powered
randomised LMS & 3VD cohorts (n=1800) & non-randomisable nested CABG
(n=649/1077 randomly selected patients) & PCI (n=198) registries. The primary (all-
cause-death) & secondary (MACCE) endpoints at 36-months were analysed in
pre-defined low (n=1156), intermediate (n=1098) & high (n=356) risk categories.
Results: Baseline characteristics demonstrated significantly more adverse co-morbidity
within the All-Comers PCI population & more complex anatomy within the All-
Comers CABG population. At 36-months, within the LMS & 3VD All-Comers PCI
cohorts, the GRC separated a low risk (GRClow) group from the higher risk (GRCint)
group, for death & MACCE. Within the All-Comers CABG population, significant
differences between GRCint-high only were evident for death & MACCE.
Comparative analyses, between CABG & PCI in the GRClow LMS cohort, revealed
no statistically significant differences in death (CABG: 5.3%, PCI: 2.7%, HR 0.51
[95% C.I. 0.18, 1.44], p=0.19) & MACCE (CABG: 18.0%, PCI: 18.5%, HR 1.02 [95%
C.I. 0.65, 1.60], p=0.94), contrary to the randomized findings. Within the GRClow
3VD population, comparability in death (CABG: 5.1%, PCI: 5.9%, HR 1.16 [95% C.I.
0.62, 2.17], p=0.65) and significantly more MACCE (CABG: 17.9%, PCI: 24.4%, HR
1.42 [95% C.I. 1.03, 1.96], p=0.031) with PCI were evident.
Proposed Algorithm
Conclusion: The identification of low Global Risk patients within the All-Comers
SYNTAX population, reflecting “real-life” contemporary practice, maintains its clinical
usefulness in risk stratifying patients.
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Background: The safety and effectiveness of Biolimus A9™-eluting stents (BES) has
been evaluated relative to sirolimus-eluting stents in the LEADERS all-comers RCT
and in several observational registries. We compared the 1-year results for the first
1102 patients in the e-BioMatrix registry with the 857 patients in the BES arm of
LEADERS and analysed how the different study designs impacted the results.
Methods: Both the e-BioMatrix PMS registry and the LEADERS RCT are all-comers,
“real world” studies, not limited by lesion length, number of treated lesions/vessels or
clinical indication (chronic stable angina vs. ACS). The baseline characteristics were
similar (ex. mean age: 64.1 vs. 64.6 (p=0.35), DM: 24% vs. 26% (p=0.32), ACS: 53%
vs. 55% (p=0.41), STEMI: 16% vs 19% (p=0.05)). LEADERS had higher proportions
of patients with prior PCI and prior MI (36% vs 25% (p<0.001) and 32% vs 21%
(p<0.001)). We compared the rates of cardiac death, MI, clinically-indicated TVR and
ARC-defined stent thrombosis at 12 months.
Results: The patients enrolled in the e-BioMatrix registry had similar rates of cardiac
death (1.7% vs 2.1%) and QW MI (0.5% vs 0.5%) compared to those in LEADERS,
but exhibited lower rates of all MI (2.5% vs. 5.8%, p<0.001), and a trend towards lower
clinically-indicated TVR (4.3% vs 5.8%, p=0.12) at 1 year. The 1-year MACE rates
were 6.7% and 10.6% for e-BioMatrix and LEADERS respectively (p<0.01). Although
e-BioMatrix showed a lower rate of early definite ST vs LEADERS (0.5% vs 1.6%,
p<0.05), the rates of late ST were similar (0.4% vs 0.4%).
Conclusion: The e-BioMatrix PMS registry confirms the good safety profile of BES
at 12 months. Even though LEADERS was an “all-comers” study, some of the adverse
event rates were lower in the e-BioMatrix registry, especially during the first 30 days,
consistent with a patient selection process and a per protocol analysis (vs. ITT in
LEADERS). This could be related to mandatory ECG and biomarker determinations
required post-procedure in LEADERS together with different MI definitions. A 25%
rate of protocol mandated angiographic FU may also contributed to higher rates of
peri-procedural MI and TVR. However, the near identical event rates beyond 30 days
for all components of MACE, suggest that under-reporting of events is unlikely to have
played a major role.
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Background: The biomechanical performance of stenting can be best understood
through a coupling of computational modeling with in vivo pathology evaluations. To
this end, finite element analysis (FEA) of stent-artery interaction can be used to
characterize vessel-specific stresses and their correlation to biologic response.
Methods: Two bare-metal stent designs differing in strut thickness were compared for
differences in vessel wall stress. FEA was used to simulate the deployment of both
stent models in a mock artery model. Acute and chronic stresses induced in the vessel
wall were determined and compared between stent models. Stents (n=4) were
implanted in a normal rabbit iliac artery at 1.3:1 stent:artery ratio. Twenty-eight days
following stenting, histomorphometric analysis was performed.
Results: Stresses were ~70% lower for thin versus thick stents. Overall, there was
increased neointimal area in the thick versus thin stents (0.86±0.07 vs 0.66±0.10
p=0.02). Though neointimal thickness above struts trended lower in thick struts
(0.02±0.00 vs 0.03±0.01, p=0.08), the change in neointimal thickness immediately
adjacent to struts was greater in thick struts (0.18±0.00 vs 0.11±0.01 p<0.01).
Neointimal thickness was similar between the two groups between struts (0.07±0.02
vs 0.03±0.01 p=0.67).
Table 1: FEA predicted principal stress (PS) and Von Mises stress (VM) at stent
crest locations.
Conclusion: Stent design impacts the stress induced in the vessel wall during and after
stent deployment. Von Mises and principal stresses are focused at stent strut contact
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